The economic potential of plant-made pharmaceuticals in the manufacture of biologic pharmaceuticals

Journal of Commercial Biotechnology

Volumn 17, Issue 2, 2011, Pages 173-182

  Kaufman, James ^a,c   Kalaitzandonakes, Nicholas ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b Department of Agribusiness Strategy ^*  (United States)

^c Economics and Management of Agrobiotechnology Center   (United States)

Author keywords

manufacturing; monoclonal antibodies; plant made pharmaceuticals; therapeutic biologics

Indexed keywords

BIOLOGIC DRUGS; COST SAVING; ECONOMIC POTENTIALS; IMMUNE DISORDERS; MANUFACTURING; PLANT-MADE PHARMACEUTICALS; PRODUCTION TECHNOLOGY; SIMULATION MODEL; THERAPEUTIC BIOLOGICS;

COMPUTER SIMULATION; ECONOMICS; INVESTMENTS; MANUFACTURE; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE;

PLANTS (BOTANY);

BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMIC ASPECT; FERMENTATION; MEDICAL RESEARCH; NEOPLASM; PLANT MADE PHARMACEUTICAL; TECHNOLOGY;

EID: 79955504025     PISSN: 14628732     EISSN: 1478565X     Source Type: Journal    
DOI: 10.1057/jcb.2010.37     Document Type: Article

References (20)

1. Aggarwal, S. (2010) What's fueling the biotech engine-2009-2010. Nature Biotechnology 28 (11) : 1165-1171.
2. IMS Health. (2010) IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $ 300.3 billion, http://www.imshealth.com, accessed 20 November 2010.
3. FDA. (2010) New molecular entity drug and new biologic approvals, http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/HowDrugsare DevelopedandApproved/DrugandBiologic ApprovalReports/ucm121136.htm, accessed 20 November 2010.
4. Federal Trade Commission. (2009) Emerging health care issues: Follow-on biologic drug competition, June, http://www.ftc.gov/os/2009/ 06/P083901biologicsreport.pdf, accessed 20 November 2010.
5. Pharmaceutical Research and Manufacturers of America. (2010) Pharmaceutical Industry Profi le 2010. Washington, DC: PhRMA.
6. Pharmaceutical Research and Manufacturers of America. (2008) Report: Medicines in Development: Biotechnology. Washington, DC: PhRMA.
7. Monroe, D., Potter, L., Millares, M., Barrueta, A. and Wagner, R. (2006) Kaiser Permanente's evaluation and management of biotech drugs: Assessing, measuring, and affecting use. Health Affairs 25 (5) : 1340-1346. (Pubitemid 44497634)
8. USDA APHIS. (2010) Release permits for pharmaceuticals, industrials, value added proteins for human consumption, or for phytoremediation granted or pending by APHIS, http://www.aphis.usda.gov/brs/ph-permits.html, accessed 29 November 2010.
9. Daniell, H., Streatfield, S. J. and Wycoff, K. (2001) Medical molecular farming: Production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends in Plant Science 6 (5) : 219-226.
10. McCloskey, R. V. (2002) Pharmaceutical production and the need for new methods. Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals; 17-18 July. Washington, DC: Pew Initiative on Food and Biotechnology, http:// pewagbiotech.org/events/0717/presentations/ McCloskey.ppt, accessed 10 November 2003.
11. McIntyre, J. (2002) Plant Made Pharmaceuticals: Overview and Benefits. St. Louis, MO. Monsanto Protein Technologies Plant-made Pharmaceuticals Briefi ng, 16-17 October.
12. Crosby, L. (2003) Commercial production of transgenic crops genetically engineered to produce pharmaceuticals. BioPharm International 16 (4) : 60-67.
13. Shanklin, T., Roper, K., Yegneswaran, P. K. and Marten, M. R. (2001) Selection of bioprocess simulation software for industrial applications. Biotechnology and Bioengineering 72 (4) : 483-489.
14. Kalaitzandonakes, N., Maltsbarger, R. and Barnes, J. (2001) The costs of identity preservation in the global food system. Canadian Journal of Agricultural Economics 49, 605-615. (Pubitemid 33720486)
15. Ramessar, K., Sabalza, M., Capell, T. and Christou, P. (2008) Maize plants: An ideal production platform for effective and safe molecular pharming. Journal of Plant Science 174 (4) : 409-419.
16. Biotechnology Industry Organization. (2002) Reference document for confi nement and development of plant-made pharmaceuticals in the United States, http://www.bio.org/healthcare/pmp/ PMPConfi nementPaper.pdf, accessed 9 March 2008.
17. Sparrow, P. A. C., Irwin, I. A., Dale, P. J., Twyman, R. M. and Ma, J. K. C. (2007) Pharma-planta: Road testing the developing regulatory guidelines for plantmade pharmaceuticals. Transgenic Research 16 : 147-161. (Pubitemid 46440619)
18. Langer, E. (2009) Trends in capacity utilization for therapeutic monoclonal antibody production. MAbs 1 (2) : 151-156.
19. Zivko, N. L., Regan, J. T., Dickey, L. F. and Woodard, S. (2009) Purifi cation of antibodies from transgenic plants. In: U. Gottschalk (ed.) Process Scale Purifi cation of Antibodies. Hoboken, NJ: Wiley- Blackwell, pp. 387-406.
20. DiMasi, J. A. and Grabowski, H. G. (2007) The cost of biopharmaceutical R & D: Is biotech different? Managerial and Decision Economics 28 : 469-479.